Stockreport

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions [Yahoo! Finance]

AIM ImmunoTech Inc.  (AIM) 
PDF Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. [Read more]